Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
NSB
vs
S
S&P/ASX 300
NSB
Over the past 12 months, NSB has underperformed S&P/ASX 300, delivering a return of -61% compared to S&P/ASX 300's 3% drop.
Stocks Performance
NSB vs S&P/ASX 300
Performance Gap
NSB vs S&P/ASX 300
Performance By Year
NSB vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
NeuroScientific Biopharmaceuticals Ltd
Glance View
NeuroScientific Biopharmaceuticals is a small drug-development company focused on peptide-based medicines for diseases that damage nerves or cause inflammation. Its lead work has centered on experimental treatments for conditions such as neurodegenerative disorders and other hard-to-treat illnesses where existing therapies are limited. At this stage, the company is mainly building and testing drug candidates rather than selling approved medicines. The company does not sell a consumer product. It makes money, or hopes to make money, by advancing its drug programs through research, preclinical work, and clinical trials, then partnering with larger pharmaceutical companies, licensing its intellectual property, or eventually selling approved drugs. Its main customers are not patients yet; instead, its economic partners are investors, research collaborators, and potential licensing or commercial partners in the drug industry. What makes the business model different is that it sits very early in the pharmaceutical value chain. NeuroScientific is trying to turn a scientific idea into a medicine, which means most of its value depends on whether its compounds can prove safe and effective in human testing. If successful, it could become a source of licensed therapies or a takeover target rather than a traditional drug maker with a broad commercial sales force.